IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 625,712 shares of the medical research company’s stock after purchasing an additional 2,496 shares during the quarter. IQVIA accounts for approximately 1.3% of B. Metzler seel. Sohn & Co. AG’s portfolio, making the stock its 17th biggest position. B. Metzler seel. Sohn & Co. AG owned about 0.34% of IQVIA worth $123,029,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. Pine Valley Investments Ltd Liability Co grew its stake in shares of IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares in the last quarter. Howard Capital Management Inc. grew its position in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after acquiring an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after purchasing an additional 56 shares in the last quarter. Cypress Wealth Services LLC boosted its stake in shares of IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 57 shares during the period. Finally, Harbor Investment Advisory LLC grew its holdings in shares of IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 58 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. UBS Group dropped their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 1.2 %

NYSE IQV opened at $177.27 on Monday. IQVIA Holdings Inc. has a 52-week low of $176.03 and a 52-week high of $253.84. The firm has a 50-day moving average price of $193.15 and a 200 day moving average price of $206.05. The stock has a market capitalization of $31.25 billion, a P/E ratio of 23.64, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.